RESUMO
The prevalence of TT virus (TTV) infection was investigated by Polymerase Chain Reaction (PCR) in low- (blood donors and healthy children/adolescents) and high-risk (hemophiliacs) groups from São Paulo, Brazil. Primers based on the untranslated region (UTR) of the viral genome proved to be much more ubiquitous, leading to much higher frequencies for both groups (>or= 81%) than the earlier N22-PCR directed to the open reading frame 1 (blood donors, 5.5%, and hemophiliacs, 42.3%). The UTR-PCR also revealed an interesting profile for healthy children/adolescents: very high prevalence at the early years and significant decrease in male teenagers. The N22-PCR, in turn, demonstrated higher frequency in hemophiliacs treated with fresh blood products (58%), than in those treated with virus-inactivated clotting factors (9.4%) and blood donors (5.5%).
Assuntos
Infecções por Vírus de DNA/epidemiologia , Torque teno virus , Adolescente , Doadores de Sangue , Brasil/epidemiologia , Criança , Pré-Escolar , Infecções por Vírus de DNA/diagnóstico , Feminino , Hemofilia A/virologia , Humanos , Masculino , Reação em Cadeia da Polimerase , Prevalência , Estudos Soroepidemiológicos , Regiões não TraduzidasRESUMO
The prevalence of TT virus (TTV) infection was investigated by Polymerase Chain Reaction (PCR) in low- (blood donors and healthy children/adolescents) and high-risk (hemophiliacs) groups from Säo Paulo, Brazil. Primers based on the untranslated region (UTR) of the viral genome proved to be much more ubiquitous, leading to much higher frequencies for both groups ( > or = 81 percent) than the earlier N22-PCR directed to the open reading frame 1 (blood donors, 5.5 percent, and hemophiliacs, 42.3 percent). The UTR-PCR also revealed an interesting profile for healthy children/adolescents: very high prevalence at the early years and significant decrease in male teenagers. The N22-PCR, in turn, demonstrated higher frequency in hemophiliacs treated with fresh blood products (58 percent), than in those treated with virus-inactivated clotting factors (9.4 percent) and blood donors (5.5 percent)